Compare FTRE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | NVAX |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 1995 |
| Metric | FTRE | NVAX |
|---|---|---|
| Price | $15.82 | $8.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 8 |
| Target Price | ★ $15.56 | $9.75 |
| AVG Volume (30 Days) | 1.4M | ★ 4.2M |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $2,759,900,000.00 | $1,064,651,000.00 |
| Revenue This Year | $3.17 | $58.91 |
| Revenue Next Year | $0.07 | N/A |
| P/E Ratio | ★ N/A | $3.87 |
| Revenue Growth | 1.88 | ★ 20.27 |
| 52 Week Low | $3.97 | $5.01 |
| 52 Week High | $19.00 | $10.65 |
| Indicator | FTRE | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 62.15 |
| Support Level | $16.98 | $7.73 |
| Resistance Level | $17.24 | $8.81 |
| Average True Range (ATR) | 1.11 | 0.45 |
| MACD | -0.36 | 0.10 |
| Stochastic Oscillator | 13.64 | 69.30 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.